Complex sentence: Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer and it is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular and kidney cancers.
Split into simpler sentences: Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer. It is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular and kidney cancers.